Edwards Lifesciences Corporation $EW Stake Cut by 2Xideas AG

2Xideas AG trimmed its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 6.6% in the third quarter, according to its most recent disclosure with the SEC. The fund owned 486,257 shares of the medical research company’s stock after selling 34,454 shares during the period. Edwards Lifesciences accounts for approximately 8.0% of 2Xideas AG’s portfolio, making the stock its 4th largest position. 2Xideas AG owned about 0.08% of Edwards Lifesciences worth $37,816,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the stock. True Wealth Design LLC increased its holdings in shares of Edwards Lifesciences by 251.5% in the third quarter. True Wealth Design LLC now owns 362 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 259 shares during the period. Hantz Financial Services Inc. increased its stake in Edwards Lifesciences by 76.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after buying an additional 164 shares during the period. Rakuten Securities Inc. increased its stake in Edwards Lifesciences by 413.7% in the 2nd quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after buying an additional 302 shares during the period. Steigerwald Gordon & Koch Inc. purchased a new position in Edwards Lifesciences during the 3rd quarter worth $30,000. Finally, Strengthening Families & Communities LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter worth $34,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total value of $87,002.22. Following the completion of the sale, the vice president owned 33,934 shares in the company, valued at $2,897,284.92. The trade was a 2.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $84.92, for a total transaction of $1,103,960.00. Following the transaction, the chief financial officer owned 39,699 shares in the company, valued at approximately $3,371,239.08. The trade was a 24.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 61,718 shares of company stock valued at $5,236,281 over the last quarter. Company insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on EW. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Wednesday, January 21st. UBS Group reaffirmed a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Piper Sandler reiterated an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. The Goldman Sachs Group reissued a “buy” rating and issued a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Finally, Truist Financial set a $89.00 price target on Edwards Lifesciences and gave the company a “hold” rating in a research note on Wednesday, February 11th. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.14.

Edwards Lifesciences Trading Down 3.3%

Shares of EW stock opened at $81.82 on Friday. The company has a market capitalization of $47.52 billion, a price-to-earnings ratio of 44.71, a PEG ratio of 2.21 and a beta of 0.93. The company has a current ratio of 3.72, a quick ratio of 3.09 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $82.41 and a 200 day moving average price of $81.58. Edwards Lifesciences Corporation has a twelve month low of $65.94 and a twelve month high of $87.89.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion for the quarter, compared to analysts’ expectations of $1.54 billion. During the same quarter last year, the firm earned $0.59 earnings per share. The business’s quarterly revenue was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Research analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.